RA Capital Management, L.P., together with related entities and individuals, reported the sale of Vor Biopharma Inc. common stock totaling $14.5 million. The dispositions took place in several transactions on April 2 and April 6, 2026, according to regulatory filings.
In aggregate, the reporting owners sold 842,282 shares of common stock. Prices realized across the transactions ranged from $16.51 to $19.06 per share. The sales coincide with marked price swings in VOR, which was down approximately 10% from a prior close of $18.05 to a then-current quote of $16.27, with InvestingPro analysis characterizing recent movements as volatile even as Fair Value calculations suggest the company remains undervalued.
Transaction detail
- April 2, 2026 - 258,475 shares sold at prices ranging from $18.05 to $19.04.
- April 2, 2026 - 1,525 shares sold at prices ranging from $19.05 to $19.09.
- April 6, 2026 - 537,754 shares sold at prices ranging from $16.25 to $17.245.
- April 6, 2026 - 44,728 shares sold at prices ranging from $17.25 to $18.20.
- April 6, 2026 - 6,775 shares sold at $18.50.
The filings identify the reporting owners as RA Capital Management, L.P., RA Capital Healthcare Fund LP, Peter Kolchinsky, and Rajeev M. Shah. These parties may be deemed to share indirect beneficial ownership of the reported shares.
Context on Vor Biopharma's finances and programs
Alongside the disclosure of insider sales, the company has announced several corporate and clinical developments. Vor Biopharma raised more than $330 million in equity capital in less than five months, extending its financial runway into early fiscal year 2029. The company also entered into a securities purchase agreement to sell in a private placement in excess of 5.3 million shares, a transaction led by TCGX that is expected to yield approximately $75 million in gross proceeds.
On the clinical front, Vor Biopharma reported dosing the first patient in a global phase 3 study of telitacicept for active primary Sjögren’s disease. That trial is planned to enroll about 250 adult patients and will evaluate changes in disease activity over a 48-week period.
Analyst coverage and recent ratings
Analyst activity accompanying these company updates includes Stifel trimming its price target for Vor Biopharma from $55 to $40 while keeping a Buy rating, citing revised financing assumptions. Jefferies initiated coverage with a Buy rating and a $50 price target, noting the company’s strategic shift toward autoimmune disease indications. That strategic shift includes the global licensing of telitacicept from RemeGen, excluding Greater China.
Data access and additional resources
InvestingPro subscribers gain access to 14 additional exclusive tips and a suite of financial metrics for VOR, including Pro Research Reports that compile detailed analyses and data into actionable formats.
The combination of disclosed insider sales, active analyst coverage, and recent financing and clinical milestones frames the current landscape for Vor Biopharma as it pursues its autoimmune strategy and manages near-term financing and trial execution.